These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 22375098)
1. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Macconell L; Brown C; Gurney K; Han J Diabetes Metab Syndr Obes; 2012; 5():29-41. PubMed ID: 22375098 [TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. MacConell L; Gurney K; Malloy J; Zhou M; Kolterman O Diabetes Metab Syndr Obes; 2015; 8():241-53. PubMed ID: 26056482 [TBL] [Abstract][Full Text] [Related]
3. Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. Vetter ML; Johnsson K; Hardy E; Wang H; Iqbal N Diabetes Ther; 2019 Aug; 10(4):1249-1270. PubMed ID: 31077072 [TBL] [Abstract][Full Text] [Related]
4. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies. Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594 [TBL] [Abstract][Full Text] [Related]
5. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Feagan BG; Macdonald JK Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889 [TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. Guja C; Frías JP; Suchower L; Hardy E; Marr G; Sjöström CD; Jabbour SA Diabetes Ther; 2020 Jul; 11(7):1467-1480. PubMed ID: 32306296 [TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. Williams-Herman D; Round E; Swern AS; Musser B; Davies MJ; Stein PP; Kaufman KD; Amatruda JM BMC Endocr Disord; 2008 Oct; 8():14. PubMed ID: 18954434 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836 [TBL] [Abstract][Full Text] [Related]
10. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467 [TBL] [Abstract][Full Text] [Related]
11. Antibiotics for induction and maintenance of remission in Crohn's disease. Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030 [TBL] [Abstract][Full Text] [Related]
12. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565 [TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. Williams-Herman D; Engel SS; Round E; Johnson J; Golm GT; Guo H; Musser BJ; Davies MJ; Kaufman KD; Goldstein BJ BMC Endocr Disord; 2010 Apr; 10():7. PubMed ID: 20412573 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. Ji L; Onishi Y; Ahn CW; Agarwal P; Chou CW; Haber H; Guerrettaz K; Boardman MK J Diabetes Investig; 2013 Jan; 4(1):53-61. PubMed ID: 24843631 [TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. Kohler S; Zeller C; Iliev H; Kaspers S Adv Ther; 2017 Jul; 34(7):1707-1726. PubMed ID: 28631216 [TBL] [Abstract][Full Text] [Related]
16. Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus. Yoon KH; Hardy E; Han J Diabetes Metab J; 2017 Feb; 41(1):69-74. PubMed ID: 28029018 [TBL] [Abstract][Full Text] [Related]
17. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Wang Y; Parker CE; Feagan BG; MacDonald JK Cochrane Database Syst Rev; 2016 May; 2016(5):CD000544. PubMed ID: 27158764 [TBL] [Abstract][Full Text] [Related]
18. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Feagan BG; Macdonald JK Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890 [TBL] [Abstract][Full Text] [Related]
19. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160 [TBL] [Abstract][Full Text] [Related]